IMM2510 (VEGF×PD-L1)

IMM2510 is a bispecific molecule with the mAb-Trap structure that targets VEGF and PD-L1 for the treatment of solid tumors. By targeting VEGF and PD-L1, IMM2510 is able to activate T-cell tumor killing activities and simultaneously inhibit tumor angiogenesis and tumor growth. Moreover, IMM2510 can also activate NK cells and macrophages through Fc-mediated ADCC/ADCP activities.

Combination Therapy with IMM27M

◆ We received IND approval from the NMPA for a Phase I clinical trial of IMM2510 in combination with IMM27M for advanced solid tumors in October 2023. The IMM2510-002 study (IMM2510+IMM27M phase Ib/II study for R/R solid tumor indication) was initiated in July 2024. First subject was dosed on July 24, 2024.